Neurocrine Biosciences Announces Disappointing Results of Valbenazine Study for Dyskinetic Cerebral Palsy Neurocrine Biosciences reveals that its Phase 3 study of Valbenazine for treating dyskinetic cerebral palsy did not meet key endpoints. The findings raise concerns for patients.

Neurocrine Biosciences Announces Disappointing Results of Valbenazine Study for Dyskinetic Cerebral Palsy #United_States #San_Diego #Neurocrine_Biosciences #Valbenazine #Dyskinetic_CP